FUTURES EXPO SERIES
DEEPMEDS
Transforming radiology with AI : minimising contrast , maximising safety
STARTUP
The DeepMeds research project aims to tackle the problem of excessive gadolinium dosage in medical imaging examinations , particularly in brain MRI scans . Currently , the standard practice of administering gadolinium-based contrast agents poses a significant risk to patient safety , with adverse effects ranging from allergic reactions to life-threatening conditions .
Sensitive groups of patients , such as those with pre-existing kidney issues , cannot receive the full dose of gadolinium-based contrast agents , leading to a risk of misdiagnosis . DeepMeds is developing an AI-powered technology that can minimise gadolinium dosage by up to 80 % while maintaining excellent image quality . This solution optimises the administration of contrast agents , ensuring that patients receive the smallest effective dose necessary for diagnostic purposes .
The researchers have taken significant steps towards implementing this solution , including conducting a multi-centre prospective study on over 1000 patients . Currently , the researchers have a prototype of their AI technology and are preparing to initiate clinical validation and pilot studies in real-world healthcare settings .
The researchers are working towards licensing their AI technology to healthcare facilities and imaging centres , with the ultimate goal of making it widely available to patients in need of safe and effective medical imaging .
> Our clinical trial indicates that DeepMeds AI can reduce contrast agent dosage by 80 % while maintaining image quality .
> Australian Health Week 2023 - 1st Place , Out of Hospital Solutions ; AstraZeneca ' s Innovative Health Pitch Fest 2023 - Runner-up .
> One of the top performers in the UNSW Health 10x Accelerator .
40 •